CNS Relapse in Non-Hodgkin Lymphoma

Patients with B-cell NHL who present with two or more extranodal sites of involvement, elevated LDH levels, and high IPI scores have high risk for CNS relapse.

Patients with diffuse large B-cell lymphoma (DLBCL) have a 50% to 60% likelihood of cure with current immunochemotherapy approaches. However, a subset of patients experience isolated central nervous system (CNS) relapse in the leptomeninges, brain parenchyma, or both. An international multicenter study group performed a retrospective analysis to assess risk factors, therapies, and outcomes for patients with brain parenchymal recurrences.

Researchers identified 113 patients (median age, 61) with brain parenchymal relapses who had achieved complete remission following primary therapy for lymphoma from 1980 through 2004; 83% had DLBCL. Most patients (88%) had extranodal disease at initial presentation; about one third had two or more involved s…

Reviewing Author

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee